Disease and Therapy Review: Non Small Cell Lung Cancer

The Non Small Cell Lung Cancer Disease and Therapy Review provides an overview of the disease and related conditions, with incidence, prevalence, and mortality numbers for major countries worldwide, information on diagnosis, and an overview of treatment. General information on the lung cancer market, as well as sales of leading drugs and therapies are provided.

Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by the senior market research team of Timely Data Resources. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Lange's Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites. Sources and references are provided.

Table of Contents:

I. OVERVIEW
General overview of the condition
Types
Staging
Survival rates
II. INCIDENCE, PREVALENCE AND MORTALITY
Incidence Table (US, Canada, Argentina, Brazil, Mexico, France, Germany, Greece, Italy, Russian Federation, Poland, Spain, Sweden, Turkey, UK, China, India, Japan, Philippines, Thailand, Egypt, South Africa, Africa, Americas, Eastern Mediterranean, Europe, Southeast Asia, Western Pacific, Worldwide)
Prevalence Table (US, Canada, Mexico, UK, France, Germany, Italy, Spain, Japan, China, India, Worldwide)
Mortality Table (US, Canada, Argentina, Brazil, Mexico, France, Germany, Greece, Italy, Russian Federation, Poland, Spain, Sweden, Turkey, UK, China, India, Japan, Philippines, Thailand, Egypt, South Africa, Africa, Americas, Eastern Mediterranean, Europe, Southeast Asia, Western Pacific, Worldwide)
III. DIAGNOSIS
Symptoms and signs
Diagnostic tools and procedure
IV. TREAMENT
Recommended treatment by stage
Chemotherapy
V. MARKET SIZE
VI. COMMENTS
VII. REFERENCES/RESOURCES


For more please visit
http://www.bharatbook.com/detail.asp?id=167603&rt=Disease-and-Therapy-Review-Non-Small-Cell-Lung-Cancer.html

OR Contact us at

Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com

Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential

The leading business intelligence provider, has released its latest research, “Oncology Market in India to 2017 – Limited Patient Affordability for High Priced Biologics Lowers Market Potential”, which provides insights into oncology sales and price forecasts until 2017. The report also examines the Indian oncology treatment usage patterns. In addition, the report also includes insights into the oncology R&D pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL).

Scope

The report covers:
- Data and analysis on the oncology market in India.
- Annualized market data for the oncology market from 2002 to 2009, with forecasts to 2017.
- Market data on the therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the oncology market includes both Indian players and foreign players.
- Key M&A activities and Licensing Agreements that took place from 2004 to 2010 in the Indian oncology market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to:
- Build effective strategies to launch their pipeline products by identifying potential of the market.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying each indication’s growth rate.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Companies Mentioned

Dr. Reddy’s Lab
Piramal Healthcare
Biocon Limited
Cipla Ltd.
Sanofi-Aventis
F. Hoffmann-La Roche Ltd/Genentech, Inc.
AstraZeneca
GlaxoSmithKline

For more please visit
http://www.bharatbook.com/detail.asp?id=167044&rt=Oncology-Market-in-India-to-2017-Limited-Patient-Affordability-for-High-Priced-Biologics-Lowers-Market-Potential.html

OR Contact us at

Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com